Premium
Biosimilar and innovator anti‐Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?
Author(s) -
Gearry Richard B
Publication year - 2016
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13357
Subject(s) - infliximab , biosimilar , medicine , adalimumab , inflammatory bowel disease , vedolizumab , drug , intensive care medicine , drug class , pharmacology , tumor necrosis factor alpha , disease , immunology